22 February, 2008
Artisan Pharma’s Lead Product, ART-123, Approved in Japan
22 October, 2007
Gary Shearman Ph.D. Joins Board of Artisan Pharma, Inc.
18 September, 2007
Artisan Pharma, Inc. And A-Bio Pharma Pte Ltd. Announce Strategic
Manufacturing Alliance on ART-123
21 August, 2007
Artisan Pharma, Inc. Launches Phase 2b Trial of ART-123 for Treatment of DIC in Sepsis
19 February, 2007
Artisan Pharma to present at The Atlas Venture Japan Biopharma Partnering Conference 2007, co-sponsored by Itochu Corp., NIF SMBC Ventures Co. Ltd., Dechert LLP and EBD Group on March 20, 2007 in Tokyo, Japan
19 February, 2007
Artisan Pharma to present at BIO-Asia Conference on January 29, 2007 in Tokyo, Japan
You must understand how to develop a drug to best serve your targeted patient populations, the caregivers administering it and the parties who will ultimately pay for it. This principle guides our work at Artisan Pharma.
Artisan Pharma is a biopharmaceutical company dedicated to bringing best-in-class critical-care and hospital-based therapeutics to patients. Our strategy is to in-license clinical-stage drug candidates and develop them for markets with clear unmet medical needs.
ART 123, our lead product, represents a promising new treatment for DIC (disseminated intravascular coagulation) in sepsis. This product might also be beneficial for a number of other indications. A product-specific ART 123 Program Advisory Board consisting of experts in sepsis, critical care and hematology will help guide the development and commercialization of this potentially breakthrough product.
In the years ahead, we will leverage the unique skills of our team, investor group and unique relationship network to expand our product portfolio and become a leader in our space. Please read on to learn more about Artisan Pharma.
